Taken together, drugs engineered to promote GIP, GLP-1 and GLP-2 receptor signalling may have potential to offer therapeutic promise for improving bone health in obesity and diabetes. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.